Shots:

• Sanofi to acquire Principia Biopharma in an all-stock transaction- at $100/share making total deal value ~$3.68B in cash. The transaction is expected to be completed in Q4’20
• The focus of the acquisition is to strengthen its R&D areas of autoimmune and allergic diseases with the expansion of the SAR442168 development program into CNS disorders. Additionally- the deal also adds rilzabrutinib to Sanofi’s portfolio of immunology and inflammation indications
• The Principia’s BTK inhibitor ‘168 is developed using its Tailored Covalency platform and was evaluated in P-IIb study for MS leading reduction of 85% Gd-enhancing T1 hyperintense lesions vs PBO. In 2017- Sanofi signed exclusive WW license agreement with Principia to develop and commercialize BTK inhibitor ‘168 in MS and other CNS diseases

Click here ­to­ read full press release/ article | Ref: Sanofi | Image: Principia Biopharma